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HLA/peptide tetramers are frequently used for ex vivo monitoring of disease- or vaccine-induced T cell
immune responses and for T cell epitope identiﬁcation. However, when low-levels HLA/peptide
tetramer-positive T cell populations are encountered, it is difﬁcult to ascertain whether this represents
a true T cell receptor (TCR)-mediated interaction or background signal. To address this issue, we have
developed a method for both HLA class I and class II tetramer assays to conﬁrm tetramer-binding to the
TCR/CD3 complex. Preincubation of T cells with anti-CD3 mAb SPV-T3b and subsequent crosslinking
interferes with the binding of HLA/peptide tetramers to the TCR/CD3 complex and thereby indicates to
what extent HLA/peptide tetramer binds through interaction with TCR/CD3 complex. SPV-T3b
pretreatment results in a 2- to 10-fold decrease in tetramer-binding intensity to antigen-speciﬁc
CD8þ or CD4þ T cells, whereas background reactivity of HLA/peptide tetramers containing HIV-
derived peptide in HIV-negative donors remained unchanged. SPV-T3b pretreatment forms a valuable
tool to verify tetramer-based detection of antigen-speciﬁc T cells during the monitoring of immune
responses in clinical studies.
& 2012 Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
HLA/peptide tetramers have become widely applied tools to
detect antigen-speciﬁc human T cells. These tetramers detect
antigen-speciﬁc T cells by binding to speciﬁc T cell receptors
(TCR) expressed by the T cells and reagents can be generated to
detect either antigen-speciﬁc CD4 or antigen-speciﬁc CD8 T cells. In
immunomonitoring studies of patients with cancer or viral infec-
tions, HLA/peptide tetramers have been proven valuable to monitor
the presence of speciﬁc immune responses against tumor antigens
or pathogens [8,12,17,19,23,24,28,31]. Furthermore, high-through-
out screening of cytotoxic T cell epitopes in pathogen genomes or
other disease-associated genes by HLA/peptide tetramer staining
has become a realistic option [2,29]. However, HLA/peptide tetra-
mer analyses consistently detect higher numbers of antigen-speciﬁc
T cells than other methods of detection, such as ELISPOT, cytokine
ﬂow cytometry and limiting dilution analysis, which are based on
the activation and/or proliferation of T cells in response to stimula-
tion with antigen [28,40]. Discrepancies in the levels of antigen-lobulin; APC, allophycocya-
MFI, mean ﬂuorescence
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cess under CC BY-NC-ND license.speciﬁc T cells measured by HLA/peptide tetramers, as compared to
the other methods might indicate that HLA/peptide tetramer
analyses overestimate the size of the antigen-speciﬁc T cell popula-
tion due to nonspeciﬁc reactivity of the HLA/peptide tetramer. On
the other hand, the discrepancies may reveal an underestimation of
the number of antigen-speciﬁc T cells detected by the other three
methods due to unresponsiveness of T cells to stimulation, despite
the expression of the speciﬁc TCR [16]. Therefore, validation of HLA/
peptide tetramer analyses for reliable detection of antigen-speciﬁc
T cells is essential for the applicability of HLA/peptide tetramer
analyses in clinical studies [41,20].
We here describe a method to verify whether the detection of
antigen-speciﬁc T cells by both HLA class I and class II tetramers,
involves binding to the TCR/CD3 complex. We have investigated
the ability of anti-CD3 and anti-TCR antibodies to interfere with
the speciﬁc binding of HLA/peptide tetramers to T cells, and found
that preincubation of T cells with monoclonal antibody (mAb)
SPV-T3b and crosslinking with goat anti-mouse immunoglobulin
(GAM-Ig) speciﬁcally decreases the speciﬁc binding of HLA/pep-
tide tetramers. This treatment enables to distinguish binding of
HLA/peptide tetramers to T cells by interaction with the TCR/CD3
complex from TCR-unrelated nonspeciﬁc binding of HLA/peptide
tetramers. This method can be used to improve the accuracy of
HLA/peptide tetramer-reactivity directly ex vivo, without in vitro
expansion or activation.
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2.1. PBMC and HLA typing
Peripheral blood mononuclear cells (PBMC) were isolated from
buffycoats from healthy donors of the Dutch Blood bank (Sanquin,
Amsterdam, The Netherlands) by standard Ficoll density centrifuga-
tion. HLA-class I typing was performed by incubating PBMC with
biotin-labeled antibodies (IgM) against HLA-A1, -A2 or -A3 (One
Lambda, Canoga Park, CA) or control biotin-labeled IgM (BD Pharmin-
gen, San Jose, CA) for 15minutes on ice. Bound antibody was detected
by incubation with Streptavidin-FITC (Immunotech, Beckman Coulter,
Fullerton, CA) for 15minutes, and ﬂow cytometry analysis using a
four-color FACS Calibur (Becton Dickinson, Pont de Claix, France).
Dead cells were excluded by propidium iodide (PI) staining. HLA class
II typing was performed by sequence based typing of HLA-DRA and
HLA-DRB alleles (Sanquin, Amsterdam, The Netherlands).
2.2. Construction of HLA class I and class II/peptide tetramers
Synthetic peptides were produced at the Netherlands Cancer
Institute by standard ﬂuorenylmethoxycarbonyl chemistry and
were 490% pure by analytical HPLC. Soluble allophycocyanin
(APC)- or phycoerythrin (PE)-labeled HLA/peptide tetramers were
generated as described [1]. HLA-A2 tetramers were produced con-
taining the following HLA-A2-binding peptides: inﬂuenza A virus
peptide (58–66) GILGFVFTL, modiﬁed MART-1 peptide (26–35,
27 A4L) ELAGIGILTV, gp100 peptide (280–288) YELPGPVTA, tyro-
sinase peptide (369–377) YMDGTMSQV, cytomegalovirus (CMV)
peptide (495–503) NLVPMVATV. PE-labeled HLA-A2/HIV tetramer
containing the p17 Gag derived SLYNTVATL peptide of the human
immunodeﬁciency virus (HIV), kindly provided by dr. D. van Baarle
(University Medical Center Utrecht, The Netherlands), was gener-
ated as described previously [34]. HLA-A1 tetramers were generated
with the inﬂuenza A virus peptide (44–52) CTELKLSDY or tyrosinase
peptide (243–251) KCDICTDEY. HLA-A3 tetramers were generated
with inﬂuenza A virus NP peptide (265–273) ILRGSVAHK. HLA/
peptide tetramers were tested for speciﬁc TCR binding using
antigen-speciﬁc T cell clones and control T cell clones, as described
[17]. HLA class II tetramers composed of HLA-DRA1n0101/
DRB1n0401 molecules and inﬂuenza A virus hemagglutinin peptide
(HA307-319, HLA-DR4/ﬂu tetramer) were generated by the method
described for murine MHC class II tetramers [25].
2.3. T cell culture
CD8þ cytotoxic T cell (CTL) clone INFA24 recognized the inﬂu-
enza A virus peptide (58–66) GILGFVFTL in HLA-A2 and was derived
from the PBMC of an HLA-A2þ healthy donor by single cell sorting of
T cells reactive with HLA-A2/ﬂu tetramers, as described [36,42]. The
CD8þ CTL clone AKR4D8 recognizes MART-1 (26–35) peptide EAA-
GIGILTV in HLA-A2 and was derived from the PBMC of an HLA-A2þ
melanoma patient by in vitro stimulation with the autologous
melanoma cell line, as described previously [11,36]. The CD8þ CTL
line ZWI29 recognizes the gp100 (280–288) peptide YLEPGPVTA in
HLA-A2 and was isolated from the PBMC of an HLA-A2þ melanoma
patient by sorting of polyclonal T cells that bound HLA-A2/gp100
tetramer by MoFlo High speed sorter (Cytomation, Fort Collins, CO).
After expansion of this population, a second round of sorting of HLA-
A2/gp100 tetramer-positive cells was performed at a density of 10
cells/well into a 96 well plate by MoFlo High speed sorter. Both CTL
clones and CTL line ZWI29 were cultured by weekly stimulation with
a feeder cell mixture consisting of 106/ml irradiated (80 Gy) allo-
geneic PBMC and 105/ml irradiated JY cells, supplemented with
100 ng/ml PHA (HA16, Buroughs Wellcome, Bechenham, UK) or
antigenic peptide and 20 IU/ml recombinant human IL-2 (Chiron,Amsterdam, The Netherlands) in Yssels medium as described [36,42].
CTL clone AKR4D8 and CTL line ZWI29 were immortalized by
transduction with a retrovirus encoding the human telomerase
reverse transcriptase (hTERT) gene, as described [11,18,36].
CD4þ T cells recognizing the inﬂuenza A virus hemagglutinin
peptide (HA307-319) in HLA-DRA1n0101/DRB1n0401 molecules
were cultured from the PBMC of an HLA-DRB1n0401þ healthy
donor who had been immunized against inﬂuenza virus. PBMC
were labeled with carboxy-ﬂuorescein diacetate succinimidyl ester
(CFSE) and cultured with the hemagglutinin peptide (HA307-319).
CD4þ T cells recognizing the inﬂuenza A virus hemagglutinin
peptide (HA307-319) in HLA-DRA1n0101/DRB1n0401 molecules
were detected by binding the HLA-DR4/ﬂu tetramer and decreased
levels of CFSE labeling, as described [22]. Cloning of the tetramer-
reactive CD4þ T cells was performed by single cell sorting of
tetramer-reactive T cells and subsequent culture, as described for
CD8þ T cell clones [36,42].
2.4. Antibodies and ﬂow cytometry
Fluorochrome-labeled monoclonal antibodies (mAb) anti-CD3-
FITC (Leu4, BD Pharmingen), anti-CD8a–FITC (Leu2a, BD Pharmin-
gen), anti-CD8b–PE (Immunotech, Beckman Colter) and anti-CD4-
APC (DAKO, Glostrup, Denmark) were used in ﬂow cytometric
analyses. Antibody incubations were performed PBS, 1% BSA, 0.05%
sodium azide at 4 1C in 96 well round-bottom plates and cells were
acquired in a four-color FACS Calibur. Viable lymphocytes were
gated by forward and side scatter proﬁle. Dead cells were excluded
by propidium iodide (PI) staining. Data were analyzed with Cell
Quest software (Immunocytometry systems, Becton Dickinson).
2.5. HLA/peptide tetramer-binding inhibition
HLA/peptide tetramer-binding inhibition assays were per-
formed using puriﬁed anti-CD3 mAbs SPV-T3b [27] and OKT-3
(ATCC, Rockville, MD [21]) or anti-TCR mAbs WT31 [26] and T10B9
[37], or isotype control IgG (all obtained from BD Pharmingen).
T cells or PBMC were preincubated with unlabeled SPV-T3b, OKT-3,
WT31, T10B9 antibodies or with control IgG at concentrations
ranging from 0.07–50 mg/ml for 15 minutes at 4 1C in 96 well
round-bottom plate in PBS, 1% BSA, 0.05% Sodium Azide (PBS/BSA)
supplemented with 1% normal mouse serum (NMS). Cells were
washed and incubated with Goat anti-mouse immunoglobulins
IgA, IgG, IgM (GAM-Ig, dilution 1:60, ICN Biomedicals, Zoetermeer,
The Netherlands) for 15 minutes 4 1C. After washing, the cells were
incubated with 500 ng HLA/peptide tetramer per 106 cells in PBS/
BSA at 37 1C for 15 minutes. HLA/peptide tetramer-binding inten-
sity was analyzed by ﬂow cytometry. The levels of binding
inhibition of tetramers by SPV-T3b pretreatment was analyzed
by the decrease in mean ﬂuorescence intensity (MFI) of the
tetramer-reactive T cells. In analyses of PBMC, blocking of tetramer
binding by SPV-T3b pretreatment resulted in a (partial) decrease in
the percentage of tetramer-reactive cells in the tetramer-positive
quadrant. To estimate the MFI of the total tetramer-positive
population after SPV-T3b pretreatment (MFIc), the MFI value of
the tetramer-reactive T cells was corrected for the ﬂuorescence
intensity of the cells, in which tetramer binding was fully blocked
(FIneg). This MFIc was calculated by the formula: MFIc¼(Tm1
MFI1þ(Tm0-Tm1) FIneg)/Tm0, in which Tm1 and MFI1 are the
percentage of tetramer-positive cells and the MFI value after SPV-
T3b pretreatment, respectively, Tm0 the percentage of tetramer-
positive cells without SPV-T3b pretreatment or after control mIgG
pretreatment and FIneg the ﬂuorescence intensity (FI) of the
quadrant setting discriminating tetramer-positive and negative
cells. FIneg is taken as MFI of the tetramer-reactive T cells, in which
tetramer-binding was fully blocked by SPV-T3b pretreatment.
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3.1. Identiﬁcation of anti-CD3 or anti-TCR mAbs that compete with
HLA/peptide tetramer-binding to human T cells
Bonaﬁde identiﬁcation of antigen-speciﬁc T cells using HLA/
peptide tetramers requires the distinction between HLA/peptide
tetramer binding to the TCR/CD3 complex and TCR-unrelated
binding. To this end, we analyzed whether anti-TCR mAbs WT31
and T10B9, and anti-CD3 mAbs SPV-T3b and OKT3, which bind to
the TCR/CD3 complex, interfered with HLA/peptide tetramer bind-
ing to antigen-speciﬁc T cells. All four antibodies bound to the HLA-
A2/inﬂuenza-speciﬁc T cell clone INFA24 in a dose dependent
fashion (Fig. 1A, left panel), which saturated at a concentration of
16 mg/ml, as measured by incubation of T cells with unlabeled
antibody followed by goat anti-mouse (GAM) Ig-FITC antibody.
When WT31, SPV-T3b or OKT3 mAbs were prebound to INFA24 T
cells and cross-linked, subsequent HLA-A2/ﬂu tetramer staining
resulted in a decreased binding of HLA/peptide tetramer as
compared to T cells without mAb preincubation (Fig. 1A, right
panel). The extent of the tetramer-binding inhibition to the T-cells
was dependent on the concentration of the TCR/CD3-reactive mAb
during the preincubation. Although anti-CD3 mAb preincubation
might induce T cell activation leading to activation-induced cell
death, antibody preincubations did not affect the viability of the T
cells, as measured by propidium iodide staining. mAb SPV-T3b was
most effective in decreasing tetramer-binding to T cell clone
INFA24, resulting in up to a four-fold decrease in mean ﬂuores-
cence intensity (MFI). Preincubation with mAb T10B9 did not
result in a decrease in tetramer binding, despite binding of this
mAb to the T cells (Fig. 1A). These results show that binding ofHLA-A2/flu tetramer-binding intensity
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Fig. 1. Inhibition of tetramer-binding to T cells by preincubation with anti-CD3 an
concentrations ranging from 0.07–50 mg/ml of anti-CD3 antibodies, SPV-T3b (J), OKT3
by incubations with GAM-Ig and HLA-A2/ﬂu tetramer. Left panel: binding intensity (MFI)
Binding intensity of HLA-A2/ﬂu tetramer to CTLINFA24 following preincubation with an
two independent experiments. B, Crosslinking of bound mAb is required for inhibition
CTLINFA24 after preincubation with 5 mg/ml SPV-T3b mAb with or without crosslinking
Graph shows representative results from three experiments.anti-CD3 mAbs SPV-T3b and OKT3 interfered more with HLA/
peptide tetramer binding than anti-TCR mAbWT31, while anti-TCR
mAb T10B9 did not affect HLA/peptide tetramer binding at all.
Based on the superior level of HLA/peptide tetramer-binding
inhibition by mAb SPV-T3b preincubation, further analyses were
performed with anti-CD3 mAb SPV-T3b.
Binding of HLA-A2/ﬂu tetramers to the INFA24 T cells was not
inhibited by preincubation with SPV-T3b alone but required
subsequent cross-linking (Fig. 1B). Furthermore, HLA/peptide
tetramer incubation prior to mAb incubation plus cross-linking
did not signiﬁcantly reduce tetramer binding intensity, which
may be due to tetramer-induced internalization of the TCR/CD3
complex. SPV-T3b mAb pretreatment was most effective when
SPV-T3b, GAM-Ig and HLA/peptide tetramer incubations were
performed as three separate consecutive incubations. Since the
incubations with anti-CD3 mAb and GAM-Ig were performed at
41C and in the presence of sodium azide, anti-CD3 mAb-induced
internalization of the TCR/CD3 complex is unlikely to occur. The
reducing effect of SPV-T3b mAb pretreatment on HLA/peptide
tetramer-binding may therefore result from sterical hindrance or
a conformational change in the CD3 complex by the immune
complexes of anti-CD3 mAb and GAM-Ig antibodies that inhibit
tetramer-binding to the TCR/CD3 complex.
Next, we analyzed the effect of SPV-T3b mAb pretreatment on
the binding of speciﬁc and control tetramers using CTL clone
INFA24, CTL clone AKR4D8 and CTL line ZWI29, speciﬁc for
inﬂuenza peptide, MART-1 peptide (27–35) or gp100 peptide
(280–288) in HLA-A2, respectively. SPV-T3b mAb pretreatment
resulted in decreased binding of speciﬁc tetramers, measured as a
ten-fold decrease in mean ﬂuorescence intensity (MFI) by all
three clones, while the background reactivity of control tetramers4
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d anti-TCR antibodies. A, CTL INFA24 was preincubated with 3-fold increasing
(’), and anti-TCR antibodies WT31 (n) and T10B9 (K) or control IgG (X), followed
of anti-CD3 or anti-TCR antibodies or control IgG to CTLINFA24 T cells. Right panel:
ti-CD3 or anti-TCR antibodies or control IgG and GAM-Ig. Data are representative of
of tetramer-binding. Graph show the binding intensity of HLA-A2/ﬂu tetramer to
by GAM-Ig, preincubation with GAM-Ig alone, or without antibody preincubation.
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T10B9 and GAM-Ig did not decrease speciﬁc tetramer-binding,
indicating that for all three TCR speciﬁcities tested mAb SPV-T3b,
but not T10B9, speciﬁcally interfered with the tetramer-binding
capacity of the TCR/CD3 complex.3.2. SPV-T3b mAb pretreatment enables distinction between HLA/
peptide tetramer-binding to T cells involving the TCR/CD3 complex
and TCR-unrelated binding
We investigated the ability of SPV-T3b mAb pretreatment to
discriminate among PBMC the antigen-speciﬁc T cells that bind
HLA/peptide tetramer through the TCR/CD3 binding from those T
cells that bind the HLA/peptide tetramer nonspeciﬁcally. PBMC of an
HLA-A2þ donor (donor A) containing a clearly detectable inﬂuenza
virus-reactive T cell population (0.64% of CD8þ T cells) was mixedHLA-A2/MHLA-A2/flu tetramer
100 101
HLA-A2
100 101 102 103 104
100 101100 101 102 103 104
HLA-A2/gp100 tetramer
CTL INFA24
(HLA-A2/flu spec.)
CTL AKR
(HLA-A2/M
Specific
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Control
tetramer
Fig. 2. SPV-T3b pretreatment exclusively decreases the binding of tetramers to antigen
speciﬁc tetramers, HLA-A2/ﬂu, HLA-A2/MART-1 and HLA-A2/gp100(280) respectively (
and GAM-Ig was measured on the tetramer-binding intensity (upper panel, bold lines)
reactivity of the T cells with control non-speciﬁc tetramers (thin lines). Data are repres
T10B9 and GAM-Ig gave similar levels of tetramer-binding as the tetramer-binding wi
Table 1
Sensitivity of detection of TCR/CD3-mediated tetramer binding in PBMC by SPV-T3b p
Tetramer-reactivity in the CD8þ T cell population
No blocking
% PBMC donor A % PBMC donor B Tetrameer Tm0
a M
100 0 A2/ﬂu 0.64 1
50 50 A2/ﬂu 0.44 1
25 75 A2/ﬂu 0.26 1
12 88 A2/ﬂu 0.21 1
6 94 A2/ﬂu 0.12 1
3 97 A2/ﬂu 0.11 1
0 100 A2/ﬂu 0.13 1
a Tm0 and Tm1 indicate the percentages of tetramer-positive T cells of the CD8þ p
b MFI0 and MFI1 indicate the mean ﬂuorescence intensity of the tetramer-positive
c MFIc indicates the mean ﬂuorescence intensity of the tetramer-reactive T cell popu
reactivity (FIneg).with PBMC of an HLA-A2þ donor without inﬂuenza-reactive T cells
(donor B) at decreasing concentrations and the level of inﬂuenza-
reactive T cells was tested by HLA-A2/ﬂu tetramer analyses with
SPV-T3b pretreatment or control IgG pretreatment (Table 1). As
expected, the percentage of inﬂuenza-reactive T cells in donor A
decreased with increasing dilution of the PBMC with donor B PBMC.
SPV-T3b pretreatment of the samples prior to tetramer staining
resulted in both a decrease in MFI and in the percentage of tetramer-
positive cells in the upper right quadrant. The decrease in the
percentage of tetramer-positive cells occurs when tetramer-binding
was fully blocked and the MFI decreased to the level of tetramer-
negative cells. To estimate the MFI of the total tetramer-positive
population after SPV-T3b pretreatment (MFIc), the MFI value of the
tetramer-reactive T cells was corrected for the ﬂuorescence intensity
of the cells, in which tetramer binding was fully blocked (FIneg), as
described in the Methods section. As shown in Table 1, at the
dilution of 12% donor A cells in the mixture, the tetramer stainingART tetramer HLA-A2/gp100 tetramer
100 101 102 103 104
HLA-A2/flu tetramer
102 103 104
/flu tetramer
100 101 102 103 104102 103 104
CTL ZWI29
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4D8
ART-1 spec.)
-speciﬁc T cells. CTLINFA24, CTLAKR4D8 and CTLZWI29 were incubated with the
upper panel, thin lines), and the effect of preincubation with 5 mg/ml SPV-T3b mAb
. Lower panel: SPV-T3b and GAM-Ig preincubation (bold lines) did not affect the
entative of three independent experiments. Preincubation with the anti-TCR mAb
thout antibody preincubation.
retreatment.
SPV-T3b pretreatment
FI0
b Tm1 MFI1 FIq MFIneg
c Fold decrease
72 0.35 132 31 86 2.0
42 0.17 69 31 46 3.1
67 0.11 51 31 40 4.2
31 0.13 47 31 41 3.2
15 0.11 42 31 41 2.8
44 0.11 77 31 75 1.9
52 0.18 108 31 138 1.1
opulation without (Tm0) or with SPV-T3b pretreatment (Tm1), respectively.
T cells without (MFI0) or with SPV-T3b pretreatment (MFI1), respectively.
lation after SPV-T3b pretreatment corrected for T cells with fully blocked tetramer-
C
D
8
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pretreatment, whereas the background reactivity in 100% donor B
(0.13%), in which no speciﬁc T cells are present, was not affected by
SPV-T3b pretreatment (1.1-fold). Table 1 shows that SPV-T3b
pretreatment can be used to detect small populations of antigen-
speciﬁc T cells in PBMC samples. SPV-T3b pretreatment decreases
the MFI about 2-fold in samples with a known tetramer-reactive
population, which justiﬁes a 2-fold decrease in MFI as a threshold in
checking the TCR/CD3-mediated tetramer-binding by SPV-T3b
pretreatment.
We extended our SPV-T3b pretreatment analyses to check the
detection of antigen-speciﬁc T cells in PBMC of 5 donors, using
HLA-A1, HLA-A2 or HLA-A3 tetramers containing peptides
derived from inﬂuenza A virus (ﬂu), cytomegalovirus (CMV),
MART-1, tyrosinase (Fig. 3 and Table 2). Fig. 3 shows a decrease
in MFI of the tetramer-reactive cells in donor 1 for HLA-A2/CMV-,
HLA-A2/MART-1- or HLA-A2/tyrosinase-reactive CD8þ T cells,
whereas the reactivity with the HLA-A2/ﬂu tetramer was not
changed by the SPV-T3b pretreatment. These results are consis-
tent with the antigen-speciﬁc proliferation upon stimulation with
CMV-, MART-1 or tyrosinase peptide, but not inﬂuenza peptide,
seen in this donor. This antigen-speciﬁc proliferation was appar-
ent from an increase in tetramer-reactive T cells in the culture
over time, whereas tetramer-reactivity remained unchanged in
control PHA-stimulated cultures. In the panel of donors contain-
ing antigen-speciﬁc T cells, as veriﬁed by in vitro peptide
stimulation, SPV-T3b pretreatment blocked tetramer-reactivities
of the CD8þ T cell population. SPV-T3b pretreatment did not
affect the background tetramer-reactivity of the CD8 negative
population (Table 2). This background reactivity is unlikely to be
mediated by the TCR/CD3 complex, as the CD8-negative popula-
tion mostly comprised CD4þ T cells that do not recognize
peptides presented in HLA-class I.
To further verify whether SPV-T3b pretreatment discriminates
between TCR-mediated binding and unrelated binding in the
CD8þ T cell population, we tested the reactivity of HLA-A2
tetramers containing the HIV-derived p17 Gag (SLYNTVATL)
peptide on PBMC of three HLA-A2þ HIV-negative healthy donors,
in whom no T cell reactivity to HIV antigens is expected to be
present. Upon acquisition of large cell samples comprising more
than 1106 PBMC, a small but detectable level of HLA/peptide
tetramer-reactivity was found in these donors. Importantly, this
reactivity remained unaffected by SPV-T3b pretreatment (Fig. 4).
In parallel analyses, the MFI of the population of HLA-A2/ﬂu
tetramer-reactive T cells in these donors decreased by SPV-T3b
pretreatment, indicating that SPV-T3b pretreatment efﬁciently
discriminates true TCR/CD3-mediated binding from background
HLA/peptide tetramer-reactivity. Furthermore, these data show
that the low-level reactivity of HLA/peptide tetramers with CD8þ
T cell populations that lack the relevant antigen-speciﬁcity is not
mediated through binding to the TCR/CD3 complex.Fig. 3. SPV-T3b pretreatment enables to distinguish tetramer-binding to the TCR/
CD3 complex from TCR unrelated binding among PBMC. A., PBMC from healthy
HLA-A2þ donors were incubated with HLA-A2/ﬂu, HLA-A2/CMV, HLA-A2/MART-1
or HLA-A2/tyrosinase tetramers (horizontal axis), after preincubation with anti-
TCR mAb T10B9 (left panel) or anti-CD3 mAb SPV-T3b (right panel), followed by
GAM-Ig. After tetramer incubation the cells were incubated with FITC-labeled
anti-CD8 mAb, which is depicted on the vertical axis. Numbers in the quadrants
indicate the MFI of tetramer-binding CD8þ T cells (upper right quadrants), or the
MFI of tetramer-binding CD8- T cells (lower right quadrants), respectively. Graphs
show that blocking of HLA-A2/CMV, MART-1 and tyrosinase tetramer-reactivity is
exclusively found in the CD8þ population, but not in the CD8- population,
indicating that the latter does not involve the TCR/CD3 complex. HLA-A2/ﬂu
tetramer reactivity was not blocked in the depicted donor. Data are representative
of three experiments performed on PBMC of two different HLA-A2þ donors, and
of one HLA-A2 negative donor. B., Graph shows an example of the eight-fold
decrease in MFI of the HLA-A2/CMV tetramer following SPV-T3b pretreatment.3.3. Testing of binding of HLA class II tetramers to the TCR/CD3
complex on T cells
Analyses of the immune response to vaccination are mostly
performed based on the reactivity of the CD8þ T cells using
HLA class I tetramers. However, successful activation of an
effector CD8þ T cell response frequently involves the activationHLA-A2/tyrosinase tetramer
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Table 2
Identiﬁcation of HLA/peptide tetramer-binding T cells among donor PBMC by SPV-T3b pretreatment.
Tetramer-reactivity in the CD8þ T cell population Tetramer-reactivity in the CD8-negative T cell population
No blocking SPV-T3b pretreatment No blocking SPV-T3b pretreatment
Donor HLA
type
Tetramer Tm0
a MFI0
b Tm1 MFI1 MFIneg MFIc
c Fold
decrease
Tm0 MFI0 Tm1 MFI1 MFIneg MFIc Fold
decrease
1 A2þ A2/CMV 1.425 583 1.500 72 43 72 8.1 0.147 613 0.129 591 43 525 1.2
1 A2þ A2/
MART-1
0.077 212 0.020 189 43 82 2.6 0.019 152 0.009 214 43 125 1.2
1 A2þ A2/tyr 0.553 71 0.022 66 29 30 2.4 0.024 397 0.023 262 29 262 1.5
2 A1þ A2þ A1/ﬂu 0.743 539 0.130 286 132 159 3.4 0.008 350 0.003 316 132 207 1.7
2 A1þ A2þ A2/ﬂu 0.340 400 0.151 83 40 59 6.8 0.175 113 0.292 199 40 199 0.6
3 A1þ A1/ﬂu 0.606 319 0.189 359 38 138 2.3 0.015 674 0.013 837 38 742 0.9
3 A1þ A1/tyr243 0.925 242 0.237 105 38 55 4.4 0.189 119 0.119 315 38 212 0.6
4 A3þ A3/ﬂu 0.122 143 0.020 130 66 70 2.0 0.013 206 0.008 174 66 129 1.6
5 A1þ A1/ﬂu 0.158 151 0.070 90 59 73 2.1 0.072 138 0.044 100 59 84 1.6
5 A1þ A1/tyr243 0.118 93 0.000 n.e. 45 45 2.1 0.077 113 0.058 124 45 104 1.1
Average decrease: 3.6 Average decrease: 1.2
a Tm0 and Tm1 indicate the percentages of tetramer-positive T cells of the CD8þ population without (Tm0) or with SPV-T3b pretreatment (Tm1), respectively.
b MFI0 and MFI1 indicate the mean ﬂuorescence intensity of the tetramer-positive T cells without (MFI0) or with SPV-T3b pretreatment (MFI1), respectively.
c MFIc indicates the mean ﬂuorescence intensity of the tetramer-reactive T cell population after SPV-T3b pretreatment corrected for T cells with fully blocked tetramer-
reactivity (FIneg).
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Fig. 4. Validation of SPV-T3b pretreatment on HIV tetramer-reactivity in HIV-negative donors. One million PBMC from three healthy HIV-negative HLA-A2þ donors were
incubated with HLA-A2/HIV or HLA-A2/ﬂu tetramers (horizontal axis), after preincubation with control murine IgG (upper panels of each tetramer analysis) or anti-CD3 mAb
SPV-T3b (lower panels), followed by GAM-Ig. After tetramer incubation the cells were incubated with FITC-labeled anti-CD8 mAb, which is depicted on the vertical axis.
Numbers in the quadrants indicate the MFI of tetramer-binding CD8þ T cells (upper right quadrants), or the MFI of tetramer-binding CD8- T cells (lower right quadrants),
respectively. Graphs show that the observed HLA-A2/HIV tetramer-reactivity is not affected by SPV-T3b pretreatment, whereas HLA-A2/ﬂu reactivity is decreased. Data are
representative of three independent experiments.
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P. Weder et al. / Results in Immunology 2 (2012) 88–9694of CD4þ T cells. An increasing number of epitopes recognized by
CD4þ T cells has been identiﬁed over the last years, and for
which class II tetramers may be generated [3,5,14,30,43,44]. As
the background reactivity of HLA-class II tetramer may vary [13],
extra testing for TCR/CD3-mediated binding is useful to improve
reliable detection of antigen-speciﬁc CD4þ T cells.
We have tested our SPV-T3b pretreatment method on HLA class
II tetramers, composed of the inﬂuenza virus hemagglutinin pep-
tide (HA307-319) bound to HLA-DRA1n0101/DRB1n0401 mole-
cules (HLA-DR4/ﬂu tetramers). As a source of PBMC containing
antigen-speciﬁc T cells, we used PBMC of a DRA1n0101/
DRB1n0401-positive donor stimulated with the inﬂuenza virus
hemagglutinin peptide (HA307-319), which resulted in an increase
in HLA-DR4/ﬂu tetramer-reactive T cells [22]. When the PBMC
were labeled with CFSE prior to peptide stimulation, the decreased
CFSE intensity of the HLA-DR4/ﬂu tetramer-positive CD4þ T cells
indicated that these cells had proliferated following peptide
stimulation (not shown). SPV-T3b pretreatment decreased the
MFI of HLA-DR4/ﬂu tetramer-reactive cells, indicating that mAbC
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Fig. 5. SPV-T3b pretreatment decreases the binding intensity of HLA class II
tetramers. (A) PBMC of an HLA-DRB1*0401þ healthy donor, which had been
cultured with the Inﬂuenza virus hemagglutinin peptide (HA307-319), were
incubated with the HLA-DR4/ﬂu tetramer-reactive T cells (upper panel), or after
preincubation with anti-TCR mAb T10B9 (middle panel), or anti-CD3 mAb SPV-T3b
(lower panel) and GAM-Ig. After tetramer incubation the cells were incubated with
APC-labeled anti-CD4 mAb, which is depicted on the vertical axis. Numbers in the
upper right quadrants indicate the MFI of tetramer-binding CD4þ T cells. (B)
Crosslinking of bound anti-CD3 mAb is required for inhibition of class II tetramer-
binding. HLA-DR4/ﬂu tetramer-reactive T cells from the PBMC in A. were cloned
by single cell sorting and tested for speciﬁc HLA-DR4/ﬂu tetramer-binding after
preincubation with 5 mg/ml SPV-T3b mAb with or without crosslinking by GAM-
Ig, preincubation with GAM-Ig alone, or without antibody preincubation. Graph
shows typical results of two experiments of a representative CD4þ T cell clone.SPV-T3b also interfered with binding of HLA class II tetramers
(Fig. 5A). As was observed for the HLA class I tetramers, pretreat-
ment with mAb T10B9 did not inhibit HLA-class II tetramer-
binding. To study the inhibition of tetramer-binding at the level
of a single TCR speciﬁcity, we generated T cell clones from the HLA-
DR4/ﬂu tetramer-reactive T cell population. As shown in Fig. 5B,
binding intensity of HLA-DR4/ﬂu tetramers to T cell clones is
almost ten-fold decreased by SPV-T3b pretreatment, indicating
that HLA-DR4/ﬂu tetramer bound to the T cells by interaction with
the TCR/CD3 complex.
Taken together, the method of SPV-T3b mAb pretreatment
described here allows one to determine whether HLA-class I and
class II tetramer-binding to T cells are TCR-mediated, and our
method is therefore a valuable tool for screening of polyclonal T
cell populations in patient-derived samples.4. Discussion
Monitoring of T cell responses in cancer patients following
vaccination with tumor antigens frequently involves the analysis
of small populations of tetramer-reactive T cells. In case of low
frequency HLA/peptide tetramer-reactive T cells, the validity of
the observed HLA/peptide tetramer staining is difﬁcult to prove
without in vitro stimulation and/or additional in vitro expansion
[19]. We describe here a new method, SPV-T3b pretreatment, to
test for binding of HLA class I/ or class II/peptide tetramers to the
TCR/CD3 complex on T lymphocytes. This method enables to
discriminate TCR/CD3-related binding of HLA/peptide tetramers
from TCR-unrelated tetramer-binding to T cells, and thereby
enhances reliable detection of antigen-speciﬁc T cells by HLA/
peptide tetramer analyses. SPV-T3b pretreatment consists of
preincubation of T cells with anti-CD3 mAb SPV-T3b followed
by incubation with GAM-Ig prior to HLA/peptide tetramer incu-
bations. Blocking of tetramer-binding by SPV-T3b pretreatment
indicates the involvement of the TCR/CD3 complex in tetramer-
binding.
HLA/peptide tetramers have mostly been validated by their
speciﬁc binding to antigen-speciﬁc T cell clones or lines, and
the absence of binding to HLA-matched control T cell clones
[23,24,28]. However, analyses of polyclonal T cells, including
PBMC, showed that HLA/peptide tetramer reactivity may also
occur in a non-antigen speciﬁc fashion [15]. The antigen-speciﬁ-
city of HLA/peptide tetramer-binding T cells can be conﬁrmed by
in vitro peptide stimulation of the T cells, inducing proliferation of
tetramer-reactive T cells, or by ﬂow cytometric sorting of tetra-
mer-binding T cells [16,33,32,12]. These validation methods
depend on the in vitro growth capacity of the HLA/peptide
tetramer-positive T cells, which may vary among antigen-speciﬁc
T cells and introduce a bias in the T cell population analyzed.
Alternatively, control samples of HLA mismatched donors have
been used to estimate the nonspeciﬁc reactivity of HLA/peptide
tetramers [23,28,35]. However, allospeciﬁcity of T cells in HLA-
mismatched control samples may result in HLA/peptide tetramer-
binding. Results of HLA mismatched control samples may there-
fore overestimate background levels of tetramer reactivity that is
not fully relevant for analyses in HLA-matched patients, which do
not have such alloreactivity. These observations underline the
need for additional control measurements in HLA/peptide tetra-
mer analyses to verify the antigen-speciﬁc binding of HLA/peptide
tetramers. The new method of SPV-T3b pretreatment we describe
here discriminates binding of HLA/peptide tetramers to the TCR/
CD3 complex from TCR-unrelated binding, and thereby represents
an internal control for HLA/peptide tetramer analyses.
The mechanism by which SPV-T3b pretreatment interferes
with the binding of tetramers to T cells may include sterical
P. Weder et al. / Results in Immunology 2 (2012) 88–96 95hindrance of tetramers for binding the TCR/CD3 complex by
bound anti-CD3 antibody immune complexes or the induction
of a conformational change in the CD3 complex that reduces
tetramer-binding. The observations that SPV-T3b pretreatment is
effective at 41C and in the presence of metabolic inhibitor sodium
azide, and is not enhanced at 371C indicate that blocking of
internalization of TCR/CD3 complexes is unlikely to be respon-
sible for the inhibitory effect of SPV-T3b pretreatment. Moreover,
sterical hindrance or stabilization of tetramer-binding by bound
antibodies has been shown for antibodies against the coreceptor
CD8, which can either decrease or enhance CD8-dependent
binding of certain MHC class I tetramers to human or murine T
cells [4,6,7,10]. Surprisingly, antibodies T10B9 and WT31, which
have been described to bind the TCRab heterodimer and not to
the CD3 complex [37,38], did not interfere with tetramer-binding
upon crosslinking. For the anti-CD3-speciﬁc antibodies that were
analyzed, interference with tetramer-binding depends on the
mAb that is used. Unfortunately, as it is presently unknown
which subunit of the CD3 complex forms the ligand of these
anti-CD3 mAbs, it remains presently unknown which CD3 chain is
the most effective target for tetramer-binding inhibition. Binding
intensities of FITC-labeled anti-human CD3 mAbs HIT3a and
UCHT1 were shown to be approximately 2-fold decreased when
HLA/peptide tetramer were prebound to human antigen-speciﬁc
T cells in one study [9]. However, only minor inhibition of HLA/
peptide tetramer binding was observed after preincubation with
the anti-CD3 mAbs, and the competing effect of mAb UCHT1 was
not conﬁrmed by others [7]. We have found that crosslinking of
the anti-CD3 mAb is required for its effect on speciﬁc tetramer-
binding performed at 37 1C, which was also reported to enhance
the speciﬁcity of tetramer-binding, as compared to 4 1C [39].
In conclusion, our method of SPV-T3b pretreatment can con-
tribute valuable data to studies of immunomonitoring of vacci-
nated patients, in which reactivity of T cells with HLA/peptide
tetramers that can be blocked by SPV-T3b pretreatment repre-
sents the total antigen-speciﬁc T cell population, including unre-
sponsive T cells.Conﬂict of interest
The authors declare no conﬂict of interest.Acknowledgments
We thank A. Pfauth, G. Sotthewes, M. Toebes, R. Gomez and E.
Taanman-Kueter for excellent technical support and dr. D. van
Baarle for kindly providing the HLA-A2/HIV tetramers. R.M. Luiten
was supported by the Dutch Cancer Society (grants NKI99-2048
and UVA2006-3606) and The Netherlands Organization for Scien-
tiﬁc Research (NWO-Vidi grant 917.56.337).References
[1] Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI,
et al. Phenotypic analysis of antigen-speciﬁc T lymphocytes. Science (New
York, NY) 1996;274:94.
[2] Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, et al.
Conditional MHC class I ligands and peptide exchange technology for the
human MHC gene products HLA-A1, -A3, -A11 and -B7. Proceedings of the
National Academy of Sciences of the United States of America
2008;105:3825.
[3] Cameron TO, Cochran JR, Yassine-Diab B, Sekaly RP, Stern LJ. Cutting edge:
detection of antigen-speciﬁc CD4þ T cells by HLA-DR1 oligomers is depen-
dent on the T cell activation state. Journal of Immunology (Baltimore, MD:
1950) 2001;166:741.[4] Campanelli R, Palermo B, Garbelli S, Mantovani S, Lucchi P, Necker A, et al.
Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR
binding and T cell activation. International Immunology 2002;14:39.
[5] Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten RM, et al.
Identiﬁcation of MAGE-3 epitopes presented by HLA-DR molecules to
CD4(þ) T lymphocytes. The Journal of Experimental Medicine 1999;189:767.
[6] Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ES, Dolton G,
et al. Anti-CD8 antibodies can trigger CD8þ T cell effector function in the
absence of TCR engagement and improve peptide-MHCI tetramer staining.
Journal of Immunology (Baltimore, MD: 1950) 2011;187:654.
[7] Denkberg G, Cohen CJ, Reiter Y. Critical role for CD8 in binding of MHC
tetramers to TCR: CD8 antibodies block speciﬁc binding of human tumor-
speciﬁc MHC-peptide tetramers to TCR. Journal of Immunology (Baltimore,
MD: 1950) 2001;167:270.
[8] Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, et al. A shift in
the phenotype of melan-A-speciﬁc CTL identiﬁes melanoma patients with an
active tumor-speciﬁc immune response. Journal of Immunology (Baltimore,
MD: 1950) 2000;165:6644.
[9] Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, Meyer EM, Rinaldo CR,
DeLeo AB, et al. Competition of peptide-MHC class I tetrameric complexes
with anti-CD3 provides evidence for speciﬁcity of peptide binding to the TCR
complex. Cytometry 2000;41:321.
[10] Holman PO, Walsh ER, Jameson SC. Characterizing the impact of CD8
antibodies on class I MHC multimer binding. Journal of Immunology
(Baltimore, MD: 1950) 2005;174:3986.
[11] Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H.
Immortalization of human CD8þ T cell clones by ectopic expression of
telomerase reverse transcriptase. Journal of Immunology (Baltimore, MD:
1950) 2000;165:4239.
[12] Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, et al. Monitoring
CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular
immune responses. Proceedings of the National Academy of Sciences of the
United States of America 2000;97:4760.
[13] James EA, LaFond R, Durinovic-Bello I, Kwok W. Visualizing antigen speciﬁc
CD4þ T cells using MHC class II tetramers. Journal of Visualized Experiments
2009.
[14] Kwok WW, Liu AW, Novak EJ, Gebe JA, Ettinger RA, Nepom GT, et al. HLA-DQ
tetramers identify epitope-speciﬁc T cells in peripheral blood of herpes
simplex virus type 2-infected individuals: direct detection of immunodomi-
nant antigen-responsive cells. Journal of Immunology (Baltimore, MD: 1950)
2000;164:4244.
[15] Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al.
Increased vaccine-speciﬁc T cell frequency after peptide-based vaccination
correlates with increased susceptibility to in vitro stimulation but does not
lead to tumor regression. Journal of Immunology (Baltimore, MD: 1950)
1999;163:6292.
[16] Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characteriza-
tion of circulating T cells speciﬁc for tumor-associated antigens in melanoma
patients. Nature Medicine 1999;5:677.
[17] Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, et al.
Immunogenicity, including vitiligo, and feasibility of vaccination with auto-
logous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Journal of Clinical Oncology : Ofﬁcial Journal of the American Society of
Clinical Oncology 2005;23:8978.
[18] Luiten RM, Pene J, Yssel H, Spits H. Ectopic hTERT expression extends the life
span of human CD4þ helper and regulatory T cell clones and confers
resistance to oxidative stress-induced apoptosis. Blood 2003;101:4512.
[19] Lyerly HK. Quantitating cellular immune responses to cancer vaccines.
Seminars In Oncology 2003;30:9.
[20] Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, et al.
Precision and linearity targets for validation of an IFNgamma ELISPOT,
cytokine ﬂow cytometry, and tetramer assay using CMV peptides. BMC
Immunology 2008;9:9.
[21] Marano N, Holowka D, Baird B. Bivalent binding of an anti-CD3 antibody to
Jurkat cells induces association of the T cell receptor complex with the
cytoskeleton. Journal of Immunology (Baltimore, MD: 1950) 1989;143:931.
[22] Novak EJ, Liu AW, Nepom GT, Kwok WW. MHC class II tetramers identify
peptide-speciﬁc human CD4(þ) T cells proliferating in response to inﬂuenza
A antigen. The Journal of Clinical Investigation 1999;104:R63–R67.
[23] Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, et al. Ex vivo
staining of metastatic lymph nodes by class I major histocompatibility
complex tetramers reveals high numbers of antigen-experienced tumor-
speciﬁc cytolytic T lymphocytes. The Journal of Experimental Medicine
1998;188:1641.
[24] Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, et al. Induction of
antigen-speciﬁc CD8þ T cells, T helper cells, and protective levels of
antibody in humans by particle-mediated administration of a hepatitis B
virus DNA vaccine. Vaccine 2000;19:764.
[25] Schepers K, Toebes M, Sotthewes G, Vyth-Dreese FA, Dellemijn TA, Melief CJ,
et al. Differential kinetics of antigen-speciﬁc CD4þ and CD8þ T cell
responses in the regression of retrovirus-induced sarcomas. Journal of
Immunology (Baltimore, MD: 1950) 2002;169:3191.
[26] Spits H, Borst J, Tax W, Capel PJ, Terhorst C, De Vries JE. Characteristics of a
monoclonal antibody (WT-31) that recognizes a common epitope on the
human T cell receptor for antigen. Journal of Immunology (Baltimore, MD:
1950) 1985;135:1922.
P. Weder et al. / Results in Immunology 2 (2012) 88–9696[27] Spits H, Keizer G, Borst J, Terhorst C, Hekman A, De Vries JE. Characterization
of monoclonal antibodies against cell surface molecules associated with
cytotoxic activity of natural and activated killer cells and cloned CTL lines.
Hybridoma 1983;2:423.
[28] Tan LC, Gudgeon N, Annels NE, Hansasuta P, O’Callaghan CA, Rowland-Jones
S, et al. A re-evaluation of the frequency of CD8þ T cells speciﬁc for EBV in
healthy virus carriers. Journal of Immunology (Baltimore, MD: 1950)
1999;162:1827.
[29] Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, et al.
Design and use of conditional MHC class I ligands. Nature Medicine
2006;12:246.
[30] Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA,
et al. Identiﬁcation of a MHC class II-restricted human gp100 epitope using
DR4-IE transgenic mice. Journal of Immunology (Baltimore, MD: 1950)
2000;164:3535.
[31] Valmori D, Dutoit V, Lienard D, Lejeune F, Speiser D, Rimoldi D, et al.
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire
of melan-A-speciﬁc CD8þ T cells in melanoma patients. Journal of Immu-
nology (Baltimore, MD: 1950) 2000;165:533.
[32] Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, et al.
Naturally occurring human lymphocyte antigen-A2 restricted CD8þ T-cell
response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer
Research 2000;60:4499.
[33] Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, et al.
Analysis of the cytolytic T lymphocyte response of melanoma patients to the
naturally HLA-An0201-associated tyrosinase peptide 368–376. Cancer
Research 1999;59:4050.
[34] van Baarle D, Kostense S, Hovenkamp E, Ogg G, Nanlohy N, Callan MF, et al.
Lack of Epstein-Barr virus- and HIV-speciﬁc CD27- CD8þ T cells is associated
with progression to viral disease in HIV-infection. AIDS (London, England)
2002;16:2001.
[35] van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, et al. On the role of
melanoma-speciﬁc CD8þ T-cell immunity in disease progression of
advanced-stage melanoma patients. Clinical Cancer Research : An Ofﬁcial
Journal of the American Association for Cancer Research 2004;10:4754.
[36] Verra NC, Jorritsma A, Weijer K, Ruizendaal JJ, Voordouw A, Weder P, et al.
Human telomerase reverse transcriptase-transduced human cytotoxic T cellssuppress the growth of human melanoma in immunodeﬁcient mice. Cancer
Research 2004;64:2153.
[37] Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, et al.
T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical
treatment of solid organ allograft rejection. American Journal of Kidney
Diseases : The Ofﬁcial Journal of the National Kidney Foundation 1989;14:61.
[38] Weiss A, Newton M, Crommie D. Expression of T3 in association with a
molecule distinct from the T-cell antigen receptor heterodimer. Proceedings
of the National Academy of Sciences United States of America 1986;83:6998.
[39] Whelan JA, Dunbar PR, Price DA, Purbhoo MA, Lechner F, Ogg GS, et al.
Speciﬁcity of CTL interactions with peptide-MHC class I tetrameric com-
plexes is temperature dependent. Journal of Immunology (Baltimore, MD:
1950) 1999;163:4342.
[40] Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-
linked immunospot, cytokine ﬂow cytometry, and tetramers in the detection
of T-cell responses to a dendritic cell-based multipeptide vaccine in patients
with melanoma. Clinical Cancer Research : An Ofﬁcial Journal of the
American Association for Cancer Research 2003;9:641.
[41] Xu Y, Theobald V, Sung C, DePalma K, Atwater L, Seiger K, et al. Validation of
a HLA-A2 tetramer ﬂow cytometric method, IFNgamma real time RT-PCR,
and IFNgamma ELISPOT for detection of immunologic response to gp100 and
MelanA/MART-1 in melanoma patients. Journal of Translational Medicine
2008;6:61.
[42] Yssel H, De Vries JE, Koken M, Van Blitterswijk W, Spits H. Serum-free
medium for generation and propagation of functional human cytotoxic and
helper T cell clones. Journal of Immunological Methods 1984;72:219.
[43] Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff Jr. CL, et al.
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted
epitope recognized by melanoma-reactive CD4(þ) T cells. Proceedings of
the National Academy of Sciences of the United States of America
2000;97:400.
[44] Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(þ) T cell
recognition of MHC class II-restricted epitopes from NY-ESO-1 presented
by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody produc-
tion. Proceedings of the National Academy of Sciences of the United States of
America 2001;98:3964.
